来源：新浪港股 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德（02359）86.94万股，每 股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 ...

责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德（02359）86.94万股，每 股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 责任编辑：卢昱君 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德（02359）86.94万股，每 股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德(02359)86.94万股，每股作 价为102.7651港元，总金额约为8934.4万港元。 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德(02359)86.94万股，每股作 价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 ...

智通财经APP获悉，香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德 (02359)86.94万股，每股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为 2989.57万股，持股比例为5.86%。 ...

辉瑞与 药明康德 达成独家合作及许可协议。 ...

辉瑞与药明康德达成独家合作及许可协议。 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking its first technology-focused stock index [1] Group 1: Index Composition and Criteria - The Technology 100 Index includes stocks that meet specific liquidity and R&D growth criteria: an average daily trading volume of at least HKD 20 million over the past six months and R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Selected companies include major players such as Tencent Holdings, Alibaba Group, CATL, Lenovo Group, Xiaomi Group, BYD, Meituan, SMIC, and WuXi AppTec [1] Group 2: Index Methodology - The index is calculated using a free-float market capitalization weighting method, with a maximum weight of 12% for any single constituent [2] - Constituents will be reviewed and adjusted biannually in June and December, with data cut-off dates on the last trading day of April and October [2] - The index aims to select technology stocks with market interest and growth potential, catering to the demand from mainland investors for technology investment opportunities in the Hong Kong market [2]

Core Viewpoint - Hong Kong Exchanges and Clearing Limited (HKEX) has launched the Hang Seng Tech 100 Index, the first index for Hong Kong stocks, which tracks the performance of the largest 100 technology companies listed on the Hong Kong Stock Exchange [1] Group 1: Index Composition and Criteria - The Hang Seng Tech 100 Index includes companies that meet specific liquidity and growth criteria: a minimum average daily trading volume of HKD 20 million over the past six months and either R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Selected companies include major players such as Tencent Holdings, Alibaba Group, BYD Company, and Xiaomi Group, among others [1] - The index covers six innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] Group 2: Index Methodology and Adjustments - The index uses a free-float market capitalization weighting method, with a cap of 12% on the weight of any single constituent [1] - Constituents are reviewed and adjusted biannually, with data cut-off dates at the end of April and October each year [1] Group 3: Liquidity and Fundamental Requirements - The index has strict liquidity and fundamental requirements: securities with an average daily trading amount below HKD 20 million or ranking in the bottom 10% by trading volume will be excluded [2] - Companies with R&D spending below 3% of revenue or revenue growth below 5% over the past two fiscal years will also be excluded, although companies listed under Chapter 18A or 18C may be exempt from these fundamental requirements [2] - This design aims to select technology stocks with market interest and growth potential, facilitating the development of related products in the mainland Chinese market and meeting the demand for technology investments from mainland investors [2]

进入12月，药明康德迎来了成立的第25个年头。四分之一世纪的时光，这家CXO企业从上海一间650平 方米的实验室，成长为在亚洲、欧洲、北美拥有超过20个研发生产基地、服务全球数千家客户的一体化 CRDMO赋能平台。在这段发展历程中，药明康德用实践诠释了何谓穿越周期的"长期主义"。 一体化CRDMO模式打通增长通路 药明康德得以在多个经济与行业周期中持续增长，核心驱动力正是其长期坚持的"一体化，端到 端"CRDMO业务模式。这一模式实现了药物发现与研究(R)、工艺开发(D)和商业化生产(M)的无缝贯 通，通过内部高效协同形成增长飞轮。 例如，药明康德在靶向蛋白降解(TPD)领域的发展，正是其CRDMO模式优势的重要体现。早在科学转 化的初期，药明康德就从R端捕捉到创新趋势，于近10年前开始布局相关能力和技术，并跟随前沿科学 陆续构建了涵盖多种分子类型的技术平台。另一方面，R端对下游D&M端业务起到引流作用。如今， 已有超过18.8万种复杂的TPD化合物从药明康德的赋能平台走出，其中70多种已进入临床前候选药物阶 段，10多种已进入后期开发阶段。 在下游，D&M端的规模化、一体化能力，实现技术的快速放大与高效产出 ...

Group 1 - The core viewpoint of the news highlights the significant increase in the success rate of national medical insurance negotiations, reaching a historical high, which is expected to encourage the development of innovative drugs in China [2] - The 2025 National Medical Insurance Drug List will add 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, marking a notable increase from 76% in 2024 [1] - The new drug list will officially implement on January 1, 2026, expanding the total number of drugs covered to 3,253, enhancing coverage in key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2 - Citic Securities believes that the successful negotiation rate for national medical insurance has reached a historical high, and the commercial insurance directory is expected to become an important growth driver, promoting the development of innovative drugs [2] - Guotai Junan Securities indicates that the recent press conference and series of discussions by the medical insurance bureau clarify future policies that support companies in "anti-involution," international expansion, and differentiated innovation, which will benefit the high-quality development of the medical device industry [2] - The China Innovation Drug ETF closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]